Metron Nutraceuticals, L.L.C. v. Thomas

2022 Ohio 79
CourtOhio Court of Appeals
DecidedJanuary 13, 2022
Docket110280
StatusPublished
Cited by5 cases

This text of 2022 Ohio 79 (Metron Nutraceuticals, L.L.C. v. Thomas) is published on Counsel Stack Legal Research, covering Ohio Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Metron Nutraceuticals, L.L.C. v. Thomas, 2022 Ohio 79 (Ohio Ct. App. 2022).

Opinion

[Cite as Metron Nutraceuticals, L.L.C. v. Thomas, 2022-Ohio-79.]

COURT OF APPEALS OF OHIO

EIGHTH APPELLATE DISTRICT COUNTY OF CUYAHOGA

METRON NUTRACEUTICALS, L.L.C., :

Plaintiff-Appellee, : No. 110280 v. :

CLAYTON THOMAS, ET AL., :

Defendants-Appellants. :

JOURNAL ENTRY AND OPINION

JUDGMENT: AFFIRMED RELEASED AND JOURNALIZED: January 13, 2022

Civil Appeal from the Cuyahoga County Court of Common Pleas Case No. CV-16-859345

Appearances:

Lewis Brisbois Bisgaard and Smith, L.L.P., Ryan K. Rubin, Daniel Leister, and Gregory P. Amend, for appellee.

Luftman, Heck & Associates, L.L.P., and Matthew L. Alden, for appellants.

KATHLEEN ANN KEOUGH, J.:

Defendant-appellant Clayton Thomas (“Thomas”) appeals from the

trial court’s judgment that granted the motion of plaintiff-appellee Metron

Nutraceuticals, L.L.C. (“Metron”) to show cause why Thomas should not be held in contempt and ordered him to pay Metron $222,360 in damages and $33,179 for its

attorney fees incurred in litigating the motion. Finding no merit to Thomas’s appeal,

we affirm.

I. Substantive and Procedural Background

In 2016, Metron filed suit against Thomas and his company,

Personalized Healthcare Solutions, L.L.C. (“PHS”). The complaint arose out of

Metron and Thomas’s business dealings.

The complaint alleged that Metron’s president, Dr. Nikolaos Tsirikos-

Karapanos, had invented a patent-pending process to make water-soluble

hydrolyzed clinoptilolite fragments, a hydrolyzed zeolite that can be consumed to

help the body eliminate toxins. The complaint further alleged that in 2014, Dr.

Tsirikos-Karapanos, Thomas, and other investors founded Metron with the

intention of selling the hydrolyzed zeolite under the name CytoDetox. Metron’s

operating agreement prohibited any member from engaging in other business

ventures that utilize zeolites or chemical solutions or formulas containing zeolites.

Thomas also signed a nonsolicitation, confidentiality, and noncompete agreement.

Nevertheless, in August 2015, without the consent or knowledge of Metron, Thomas

formed PHS, a zeolite distribution company, in direct competition with Metron.

Then, again without Metron’s knowledge or authorization, Thomas contacted

Metron’s packaging department and ordered it to ship all of Metron’s remaining

CytoDetox product, or 2,616 bottles, to Thomas’s residence in Tacoma, Washington.

Despite demands, Thomas refused to return the CytoDetox to Metron. Metron’s complaint asserted claims against Thomas and PHS for

breach of fiduciary duty, breach of the duties of loyalty and care, breach of contract,

conversion and/or civil theft, violation of the Uniform Trade Secrets Act, fraud in

the inducement, tortious interference with contract and business relations, and

unjust enrichment. The complaint also sought temporary and permanent injunctive

relief.

After a hearing, the trial court granted a preliminary injunction. It

found that the evidence presented at the hearing

demonstrated that not only are Defendants engaging in competitive businesses in violation of contracts and agreements with Metron, but Plaintiff presented evidence of Defendants’ internet-based websites and podcasts and radio publications/broadcasts that Metron opined were not authorized and amount to misinforming the public. Further, based on Plaintiff’s evidence, Defendants are selling product either directly stolen from Metron or manufactured by way of violating Metron’s trade secrets, patents, and confidentiality agreements. The evidence also indicated that Defendants have forged and misrepresented contracts, and Defendants have misrepresented the product, resulting in direct harm to Plaintiff. These acts also violate Thomas’s fiduciary duties to Metron, as he is a shareholder.

Subsequently, after a hearing, the trial court granted default

judgment to Metron. The trial court’s judgment ordered Thomas to forfeit his 15.99

percent share in Metron and pay compensatory damages and ordered permanent

injunctive relief against Thomas and PHS.

Three times thereafter, the trial court found Thomas in civil contempt

of court for failing to comply with the trial court’s injunction. Each time, the court

had ordered various sanctions and purge conditions, none of with which Thomas complied. When Thomas failed to appear at a purge hearing despite an order to do

so, the court found him in criminal contempt and issued a warrant for his arrest.

Thomas and PHS then filed a motion for relief from judgment. At the

hearing on the defendants’ motion, the court also heard argument regarding

Thomas’s contempt. The trial court found that Thomas was still in contempt, had

made no effort whatsoever to purge himself of contempt, and continued to engage

in activities from which he had been enjoined. The court ordered Thomas remanded

to the Cuyahoga County Jail to serve three days’ imprisonment.

Subsequently, after the court denied the defendants’ motion for relief

from judgment, in an effort to bring finality to the matter, the parties filed a joint

motion for relief from judgment requesting that the trial court enter an agreed

judgment. The trial court granted the motion and entered the agreed judgment,

which among other things, ordered that Thomas and PHS were to “immediately”

return to Metron all remaining bottles of CytoDetox in Thomas’s possession or

under his control.

In July 2020, Metron filed a motion for Thomas to show cause as to

why he should not be held in contempt for failing to comply with the agreed

judgment. The trial court conducted an evidentiary hearing, after which both parties

filed post-hearing briefs. In its post-hearing brief, Metron requested its attorney

fees incurred in litigating the motion.

In its journal entry granting Metron’s motion to show cause (which

the trial court concluded was “essentially a motion to enforce a settlement agreement”), the trial court found that although it had ordered Thomas and PHS

three times to return the 2,616 bottles of CytoDetox to Metron (i.e., in the

preliminary injunction, the permanent injunction, and the agreed judgment entry),

“none (zero) of the 2,616 bottles were returned.” The court found that “because Mr.

Thomas failed to return any of the CytoDetox bottles, in violation of the court’s

orders and his own agreement,” Metron was entitled to $222,360 in damages, which

the court determined was the fair market value of the unreturned bottles. The court

also found that Thomas and PHS had violated the agreed judgment in other ways,

but that Metron had not proved any damages regarding those violations.

With respect to attorney fees, the court found that Metron’s request

for $31,609 in attorney fees and $1,570 for litigation support incurred “due to Mr.

Thomas’s violation of the settlement agreement” was “reasonable based on the

experience of counsel and on the rate charged within this area of law in Cleveland,

Ohio.” Accordingly, it awarded Metron $33,179 in attorney fees. This appeal

followed.

II. Law and Analysis

A. Damages Award

In his first assignment of error, Thomas contends that the trial court

abused its discretion in awarding $222,360 to Metron for his failure to comply with

paragraph 9 of the agreed judgment entry, which ordered him to “immediately”

return the 2,616 bottles of CytoDetox to Metron.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Williams v. Hung
2024 Ohio 5093 (Ohio Court of Appeals, 2024)
Alami v. Khalid
2024 Ohio 2456 (Ohio Court of Appeals, 2024)
Taylor v. BASF Catalysts, L.L.C.
2023 Ohio 1136 (Ohio Court of Appeals, 2023)
Eagle Realty Invests., Inc. v. Dumon
2022 Ohio 4106 (Ohio Court of Appeals, 2022)
WSB Rehab. Servs. Inc. v. Cent. Accounting Sys. Inc.
2022 Ohio 2160 (Ohio Court of Appeals, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
2022 Ohio 79, Counsel Stack Legal Research, https://law.counselstack.com/opinion/metron-nutraceuticals-llc-v-thomas-ohioctapp-2022.